These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.
318 related articles for article (PubMed ID: 26470799)
1. PDE-5 Inhibitors for BPH-Associated LUTS. Brousil P; Shabbir M; Zacharakis E; Sahai A Curr Drug Targets; 2015; 16(11):1180-6. PubMed ID: 26470799 [TBL] [Abstract][Full Text] [Related]
2. [PDE5: A new therapeutic target for lower urinary tract symptoms/ benign prostatic hyperplasia combined with erectile dysfunction]. Xu Z; Jia RP Zhonghua Nan Ke Xue; 2018 Apr; 24(4):355-359. PubMed ID: 30168958 [TBL] [Abstract][Full Text] [Related]
3. Efficacy and Safety of a Fixed-Dose Combination Therapy of Tamsulosin and Tadalafil for Patients With Lower Urinary Tract Symptoms and Erectile Dysfunction: Results of a Randomized, Double-Blinded, Active-Controlled Trial. Kim SW; Park NC; Lee SW; Yang DY; Park JK; Moon DG; Yang SK; Lee SW; Moon KH; Ahn TY; Kim SW; Park K; Min KS; Ryu JK; Son H; Jung J; Hyun JS J Sex Med; 2017 Aug; 14(8):1018-1027. PubMed ID: 28760246 [TBL] [Abstract][Full Text] [Related]
4. Critical analysis of the relationship between sexual dysfunctions and lower urinary tract symptoms due to benign prostatic hyperplasia. Gacci M; Eardley I; Giuliano F; Hatzichristou D; Kaplan SA; Maggi M; McVary KT; Mirone V; Porst H; Roehrborn CG Eur Urol; 2011 Oct; 60(4):809-25. PubMed ID: 21726934 [TBL] [Abstract][Full Text] [Related]
5. The efficacy of PDE5 inhibitors alone or in combination with alpha-blockers for the treatment of erectile dysfunction and lower urinary tract symptoms due to benign prostatic hyperplasia: a systematic review and meta-analysis. Yan H; Zong H; Cui Y; Li N; Zhang Y J Sex Med; 2014 Jun; 11(6):1539-45. PubMed ID: 24621088 [TBL] [Abstract][Full Text] [Related]
6. [Treatments of erectile dysfunction combined with lower urinary tract symptoms associated with benign prostatic hyperplasis]. Jin Z; Xin ZC Beijing Da Xue Xue Bao Yi Xue Ban; 2011 Aug; 43(4):632-5. PubMed ID: 21844982 [TBL] [Abstract][Full Text] [Related]
7. Tadalafil - a therapeutic option in the management of BPH-LUTS. Carson CC; Rosenberg M; Kissel J; Wong DG Int J Clin Pract; 2014 Jan; 68(1):94-103. PubMed ID: 24341303 [TBL] [Abstract][Full Text] [Related]
8. Sexual function in men with lower urinary tract symptoms and prostatic enlargement secondary to benign prostatic hyperplasia: results of a 6-month, randomized, double-blind, placebo-controlled study of tadalafil coadministered with finasteride. Glina S; Roehrborn CG; Esen A; Plekhanov A; Sorsaburu S; Henneges C; Büttner H; Viktrup L J Sex Med; 2015 Jan; 12(1):129-38. PubMed ID: 25353053 [TBL] [Abstract][Full Text] [Related]
9. Tadalafil once daily in the treatment of lower urinary tract symptoms (LUTS) suggestive of benign prostatic hyperplasia (BPH) in men without erectile dysfunction. Brock G; Broderick G; Roehrborn CG; Xu L; Wong D; Viktrup L BJU Int; 2013 Nov; 112(7):990-7. PubMed ID: 23937669 [TBL] [Abstract][Full Text] [Related]
11. Microvascular dysfunction and efficacy of PDE5 inhibitors in BPH-LUTS. Cellek S; Cameron NE; Cotter MA; Fry CH; Ilo D Nat Rev Urol; 2014 Apr; 11(4):231-41. PubMed ID: 24619381 [TBL] [Abstract][Full Text] [Related]
12. Effects of tadalafil on lower urinary tract symptoms secondary to benign prostatic hyperplasia and on erectile dysfunction in sexually active men with both conditions: analyses of pooled data from four randomized, placebo-controlled tadalafil clinical studies. Porst H; Roehrborn CG; Secrest RJ; Esler A; Viktrup L J Sex Med; 2013 Aug; 10(8):2044-52. PubMed ID: 23782459 [TBL] [Abstract][Full Text] [Related]
13. BPH/LUTS and ED: common pharmacological pathways for a common treatment. Fusco F; D'Anzeo G; Sessa A; Pace G; Rossi A; Capece M; d'Emmanuele di Villa Bianca R J Sex Med; 2013 Oct; 10(10):2382-93. PubMed ID: 23875757 [TBL] [Abstract][Full Text] [Related]
14. Medical therapy for benign prostatic hyperplasia: a review. Van Asseldonk B; Barkin J; Elterman DS Can J Urol; 2015 Oct; 22 Suppl 1():7-17. PubMed ID: 26497339 [TBL] [Abstract][Full Text] [Related]
15. Role of phosphodiesterase type 5 inhibitors for lower urinary tract symptoms. Miller MS Ann Pharmacother; 2013 Feb; 47(2):278-83. PubMed ID: 23386068 [TBL] [Abstract][Full Text] [Related]
16. A comparative randomized prospective study to evaluate efficacy and safety of combination of tamsulosin and tadalafil vs. tamsulosin or tadalafil alone in patients with lower urinary tract symptoms due to benign prostatic hyperplasia. Singh DV; Mete UK; Mandal AK; Singh SK J Sex Med; 2014 Jan; 11(1):187-96. PubMed ID: 24165272 [TBL] [Abstract][Full Text] [Related]
17. A new experimental rat model of erectile dysfunction and lower urinary tract symptoms associated with benign prostatic hyperplasia: the testosterone-supplemented spontaneously hypertensive rat. Oudot A; Oger S; Behr-Roussel D; Caisey S; Bernabé J; Alexandre L; Giuliano F BJU Int; 2012 Nov; 110(9):1352-8. PubMed ID: 22448674 [TBL] [Abstract][Full Text] [Related]
18. The use of PDE-5 inhibitors in the treatment of lower urinary tract symptoms due to benign prostatic hyperplasia. Lythgoe C; McVary KT Curr Urol Rep; 2013 Dec; 14(6):585-94. PubMed ID: 24136683 [TBL] [Abstract][Full Text] [Related]
19. Combination therapies for improved management of lower urinary tract symptoms/benign prostatic hyperplasia. De Nunzio C; Presicce F; Tubaro A Drugs Today (Barc); 2016 Sep; 52(9):501-517. PubMed ID: 27883117 [TBL] [Abstract][Full Text] [Related]
20. Efficacy and safety of tadalafil once daily in the treatment of men with lower urinary tract symptoms suggestive of benign prostatic hyperplasia: results of an international randomized, double-blind, placebo-controlled trial. Porst H; Kim ED; Casabé AR; Mirone V; Secrest RJ; Xu L; Sundin DP; Viktrup L; Eur Urol; 2011 Nov; 60(5):1105-13. PubMed ID: 21871706 [TBL] [Abstract][Full Text] [Related] [Next] [New Search]